Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24567736 | 1.00 | GAA (0.61) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL14241975 | 0.90 | GAA (0.65) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL23480154 | 0.90 | GAA (0.65) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL27639742 | 0.85 | GAA (0.51) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL31017670 | 0.85 | GAA (0.49) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL10307933 | 0.83 | PSMB5 (0.52) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL15199110 | 0.83 | GAA (0.58) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL15715059 | 0.83 | GAA (0.49) | GAACYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL27639734 | 0.82 | NAAA (0.53) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 | |
| SCHEMBL13746392 | 0.81 | GAA (0.56) | GAACYP2C19CYP2C9EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-8575199-B2 | Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists | PURDUE PHARMA L.P. (US) | 2013-11-05 | — | — | US | disclosed |
| CN-103189446-A | Stereocomplex polylactic acid film and resin composition | TEIJIN LTD | 2013-07-03 | — | — | CN | disclosed |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-07-12 | — | — | US | disclosed |
| CN-102268157-A | Polypropylene resin composition | — | 2011-12-07 | — | — | CN | disclosed |
| CN-101568585-B | Novel polyolefin resin composition and molded resin obtained therefrom | NEW JAPAN CHEM CO LTD | 2011-08-10 | — | — | CN | disclosed |
| CN-1898317-B | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101568585-A | Novel polyolefin resin composition and molded resin obtained therefrom | NEW JAPAN CHEM CO LTD (JP) | 2009-10-28 | — | — | CN | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| CN-1898317-A | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | GAA 3083/4885CYP2C19 935/4885CYP2C9 1406/4885 |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | GAA 3083/4885CYP2C19 935/4885CYP2C9 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.